Tag Archives: BIO Investor Forum

U.S. Patent for Resolvin to Enter Human Trials

Resolvyx Pharmaceuticals, Inc. announced the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) for RX-10045, a Resolvin therapeutic set to enter clinical trials. RX-10045 is a topical eye drop that treats chronic dry eye syndrome. Resolvins are naturally-occurring, small molecule lipid mediators that can be used to treat a wide range of diseases, including asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others. Resolvyx has more Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

What’s New at ImmunoVaccine Technologies

An interview with Dr. Randal Chase, President & CEO of ImmunoVaccine Technologies: Can you describe the top priorities or upcoming milestones for your company? Our first priority is to show the safety of our DepoVax™ vaccine enhancement technology in humans by taking our first product, DPX-0907 therapeutic cancer vaccine into Phase 1 clinical trials. We are anticipating filing an IND for DPX-0907 by the end of 2009 and initiating the trial in Q1 of 2010. Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

A Word with Calistoga Pharmaceuticals’ CEO

An interview with Dr. Carol Gallagher, Pharm.D., CEO of Calistoga Pharmaceuticals: Can you describe the top priorities or upcoming milestones for your company? 4Q 2009: Reporting updated efficacy and safety data from the ongoing CAL-101 Phase 1 trial in patients with hematologic malignancies 1H 2010: Initiating a Phase 2 registration program for CAL-101 Initiating a Phase 2 trial evaluating CAL-263, a novel oral delta isoform-selective PI3K inhibitor, in patients with asthma Initiating a Phase 1 Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

XOMA to Repay Goldman Sachs Loan in Full

XOMA Ltd. (Nasdaq:XOMA) announced a plan to repay its loan with Goldman Sachs Specialty Holdings, Inc. (Goldman Sachs) through a combination of funds. Payment will include proceeds from Genentech’s payment to XOMA for the buyout of its LUCENTIS(R) royalty obligation to XOMA, the sale of common stock and funds from an existing restricted cash account reserved for loan repayment. The repayment plan resolves the uncertainty about the loan that arose from the sudden and unexpected Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Newron Announces Positive Results for Ralfinamide

Newron Pharmaceuticals SpA, announced positive preclinical study results showing that ralfinamide has statistically significant benefits against spontaneous chronic pain in an experimental model of central pain. Ralfinamide has shown positive results in chronic pain on CNS targets, in addition to its known peripheral mechanisms; Ralfinamide’s unique ability to affect central targets widens its broad spectrum of analgesic mechanisms, supporting its therapeutic potential for alleviating Neuropathic Low Back Pain (NLBP) in the ongoing SERENA Phase IIb/III Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,